‘State-of-the-art’ models can struggle with basic enterprise tasks: AI unicorn executive


“State-of-the-art” (Sota) artificial intelligence models excel at solving complex Olympiad maths but still struggle with everyday enterprise tasks, according to an executive from a top AI unicorn in the US.
David Meyer, senior vice-president of product at US data processing and analysis company Databricks, told the South China Morning Post in a recent interview that the very traits making models state-of-the-art could cause issues in basic office work. For instance, when tasked with identifying an erroneous number on an invoice, a Sota model “will oftentimes fix the mistake” rather than simply extracting the error for downstream correction, he said.
The discrepancy extends to other highly technical domains as well. While advanced models such as Anthropic’s Claude were powerful at coding, they could lag in tasks like data engineering compared with models with significantly more specialised training and data in this area, according to Meyer.

Data engineering involves transforming datasets at scale and performing cleaning tasks, such as handling null values and zeros.

“A single model, no matter how large, can’t be equally good at all things,” he said.

To solve these specific complexities more efficiently, Meyer pointed to the use of small open-source models refined with reinforcement learning. This allowed for a specific purpose at a level of training cost “orders of magnitude lower” than Sota models, according to Meyer.
The very traits making models “state-of-the-art” may cause issues in basic office work, according to David Meyer. Photo: Handout
The very traits making models “state-of-the-art” may cause issues in basic office work, according to David Meyer. Photo: Handout
  • Related Posts

    Hong Kong homebuyers extend sell-out streak amid renewed confidence in market

    Hong Kong homebuyers’ strong demand for new flats extended a streak of brisk sales for developers with one project selling out in a single day, underscoring the city’s broader recovery…

    Continue reading
    How Chinese drug makers are tackling Western dominance in US$16 billion Parkinson’s race

    Chinese biomedical companies deploying cutting-edge technologies are emerging as serious competitors to Western dominance in the race to treat Parkinson’s disease, in a market that could reach US$16 billion over…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *